In the prospective single-arm ACCELERATE trial 150 patients with radiographic evidence of advanced lung cancer had serum testing for circulating tumor DNA with next generation sequencing (NGS). This was followed by standard diagnostic biopsy with histologic and NGS analysis. Of 104 with subsequently biopsy-proven non-small cell lung cancer (NSCLC), 90 patients had non-squamous histology of whom half (n=45) had driver mutations detected on NGS. Most importantly, the primary endpoint of median time from referral to initiation of treatment was slashed: 39 days for enrollees versus 62 for matched controls. | García-Pardo, JAMA Netw Open 2023
